

Implanet announces its 2017 financial calendar

Bordeaux, Boston, December 13, 2016: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible; OTCQX: IMPZY), a medical technology company specializing in vertebral and knee-surgery implants, today announced today its schedule for the publication of financial information for 2017.

Event	Dates*
2016 Full-Year Sales	January 16, 2017
2016 Full-Year Results	March 28, 2017
2017 First-Quarter Sales	April 18, 2017
Annual General Meeting	May 23, 2017
2017 First-Half Sales	July 18, 2017
2017 First-Half Results	September 19, 2017
2017 Third-Quarter Sales	October 17, 2017

(*): Press releases are published before market opens. Subject to modification.

DISCLAIMER

This press release contains forward-looking statements related to Implanet and its activities. Implanet estimates that these forward-looking are based on reasonable assumptions. No guarantee is given as to these forecasts being achieved, which are subject to risks, including those described in Implanet Reference Document registered with the French *Autorité des marchés financiers* (a copy of which is available on www.implanet-invest.com), and to the development of economic conditions, the financial markets and the markets in which Implanet operates. Forward-looking statements included in this press release are also subject to risks unknown for Implanet or not considered by Implanet as significant as of today. The Company's future performance, the Company's financial position, results, cash-flows and developments in the sector may differ materially due to the realization of one of those risk factors.



About IMPLANET

Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 48 people and recorded 2015 sales of €6.7 million. For further information, please visit www.implanet.com

Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013.
IMPLANET is listed on Compartment C of the Euronext™ regulated market in Paris.

IMPLANET

Ludovic Lastennet

CEO

Tel.: +33 (5) 57 99 55 55

investors@implanet.com

Alpha Bronze
US – Investor Relations
Pascal Nigen
Tel.: +1 (917) 385-2160
implanet@alphabronze.net

NewCap
Investor Relations – France
Florent Alba
Tel.: +33 (5) 57 99 55 55
investors@implanet.com